Method for improving adaptation possibilities, and psychofunctional state correction in patients with harmful working conditions

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used to improve the adaptation possibilities and to correct the psychofunctional state in the patients with harmful working conditions. That is ensured by recommending a relaxed or partial load or motion state. Health food from Diet No.5, intake of low-mineralised (3.7 g/dm3) low-carbonate sulphate-hydrocarbonate sodium-calcium mineral water of 'Slavyanovskaya' source (Zheleznovodsk mineral water), 3.3 g/kg of body weight (200-250 ml) per one intake, 45 minutes before meals, 3 times a day. The patient takes baths with mineral water of the same composition at water temperature 36-37°C for 15 minutes, every second day, in the therapeutic course consisting of 10 procedures. The aromatherapy-assisted psychological autotraining sessions are prescribed for 14 days. Furthermore, Adaptol is prescribed for 14-day intake in a dose of 500 mg 3 times a day.

EFFECT: invention provides an improved adaptation, autonomic regulation, peroxide homeostasis, digestive functions, mental and emotional status of the patients exposed to the adverse effects of environmental factors due to the integrated treatment.

5 tbl, 3 ex

 

The invention relates to medicine, namely to the section of internal diseases, and for improving the effectiveness of rehabilitation treatment of employees of enterprises with harmful working conditions.

There is a method of treatment of persons working in hazardous conditions, exposed to ionizing radiation during the liquidation of the accident at the Chernobyl NPP (research report "Development of methods of treatment and rehabilitation physical factors of patients with common diseases (Prevention hematological, immunological and hormonal disorders in persons exposed to the adverse effects of environmental factors), Pyatigorsk, 1991. № state registration 018943216). This method involves gently-training regimen physical activity, healthy food in the diet №5, the ingestion of low-mineralized (3.7 g/DM3) Slavophiles sulphate-hydrocarbonate calcium-sodium mineral water Slavyanovskaya source (Zheleznovodsk type of mineral water) in a volume of 200-250 ml per reception 3 times a day, as well as mineral baths identical composition at a water temperature of 36-37°C for 15 minutes a day, 10 sessions of treatment.

There is a method of treatment causes beneficial changes in the condition of patients affected by the harmful and dangerous effects, however, are not always p is adequate to achieve the desired result. Given that we observe a group of patients (employees of enterprises with harmful working conditions in contact with ionizing radiation, chemical and biological toxicants and psychological overloads) similar in nature harmful effects, this method is adopted as a prototype, its application we studied 30 of the observed patients. The analysis of the nature of the violations, when exposed to harmful working conditions, and especially the influence of pharmacopaeia of Adaptol on the human body has allowed us to assume that a comprehensive medical Spa factors and drug drug will have a positive therapeutic effect. This proceeded from the data about the role of Adaptol as day trancvillizator properties adaptogene, and the importance of action of the drug on the activity of the structures included in the limbic-reticular complex, emotional zone of the hypothalamus and the ability to eliminate worry, anxiety and fear. Powerful vegetationa action makes extensive use of Adaptol in the treatment of a range of disadaptation States and to achieve anti-stress and stress-protective effect (Sgouridis, Liku, 2004. No. 5-6; Innoscript, Avenuewest, Avery. Journal of biological medicine (2007, No. 4); Warmerthan "Doctorr." (2009, №6).

Technical achiev what tatom of the proposed method is to increase the adaptive capacities of the organism, correction psychofunctionalism condition of patients, and rehabilitation treatment of employees of enterprises with harmful working conditions.

This technical result is achieved by the fact that the applied method of treatment that includes gentle or gently-training regimen physical activity, meals according to the diet N5, the ingestion of low-mineralized (3.7 g/DM3) Slavophiles sulphate-hydrocarbonate calcium-sodium mineral water Slavyanovskaya source (Zheleznovodsk type of mineral waters) of 3.3 g/kg body weight (200-250 ml) for one admission 45 minutes before meals, 3 times a day, the use of mineral baths with mineral water of identical composition at a water temperature of 36-37°C for 15 minutes, every day, 10 sessions of treatment sessions and psychological auditory training with aromatherapy within 14 days, characterized in that it further has appointed internal reception of pharmacopaeia - Adaptol within 14 days 500 mg 3 times per day.

The proposed method of treatment was performed as follows: the patients were prescribed gently-training regimen physical activity, healthy food in the diet №5, internal reception mineralized (3.7 g/DM3) Slavophiles sulphate-hydrocarbonate calcium-sodium mineral water Slavyanovskaya source (Zheleznovodsk terminalling water) of 3.3 g/kg body weight (200-250 ml) for one admission 45 minutes before a meal, 3 times a day, the use of mineral baths with mineral water of identical composition at a water temperature of 36-37°C for 15 minutes, every day, 10 sessions of treatment sessions and psychological auditory training with aromatherapy within 14 days, characterized in that it further has appointed internal reception of pharmacopaeia - Adaptol within 14 days 500 mg 3 times a day. The method can be illustrated by the following examples:

1. Patient SNI, 55 years of age, was treated in Zheleznovodsk clinic FGI "Pyatigorsk, GNIIT FMBA of Russia" 11.08. on 31.08.2011, history No. 1377). Diagnosis: Chronic superficial gastritis in remission. IBS with constipation. Polysegmental osteochondrosis. Privrzenost 1 list, contact with radioactive products. The duration of 20 years. The beginning of the disease in 2000. Were outpatients and inpatient without much effect. Spa treatment for the first time. Complaints at admission: expressed General weakness, fatigue, edginess, inner turmoil, frequent headaches, dizziness, insomnia, increased sweating. Periodic pains in the epigastric region, heartburn, flatulence, constipation. Palpation of the abdomen moderate sensitivity in the epigastric region. The liver was increased by 1 cm, the edge sharp, supple, smooth. The symptom is Ortner and Kera negative. Objective: HELL 120/70 mm Hg, pulse 72 in one minute. Dermographism red, persistent instability in the Romberg position. ECG: signs of violations of repolarization in the back wall of the left ventricle. Blood count: HB - 153 g/l; leukocytes 5,8×109/l (e - 1, P - 1, p - 69, L - 23, M - 6). Bilirubin total - 22,4 µmol/l; direct - 1,4; alkaline phosphatase - 148 u/l; ALT - 43,1 U/l; AST - 33,2 U/l; GGT - 36,1 u/l, cholesterol - 6.1 mmol/l; LDH - 281 U/l; ck - 124 U/l; lactate - 2.4 mmol/l; pyruvate - 0.28 mmol/l; glucose - 5.4 mmol/l; amylase blood 118,4 u/l; uric acid - 324 μmol/l; catalase - 0,25 mkat/l; MDA - 3.9 µmol/l; the average molecule is 0.27 c.u; Spiroarteriokardioritmografii (SAQR) - expressed increased autonomic activity, expressed parasympathicotonia. Ultrasound - structural changes in the liver, thickening of the gallbladder wall. The patient is assigned gently-training regimen physical activity, diet nutrition diet №5, internal reception Slavophiles sulphate-hydrocarbonate sodium-calcium mineral water Slavyanovskaya source 250 ml 3 times a day for 45 minutes before a meal, mineral baths from the identical mineral water temperature 36-37°C, exposure 15 minutes through the day for a course of 10 treatments, psychological sessions of autogenic training with aromatherapy. The patient took Adaptol 500 mg 3 times a day for 14 days. As a result of sanatorium-the Wen Hui holiday treat positive dynamics of clinical and paraclinical parameters. Decreased General weakness, disappeared fatigue, irritability, headaches, normalized sleep, decreased dyspeptic symptoms. Palpation of the abdomen painless. The liver is not enlarged.

Objective: HELL 120/80 mm Hg, pulse 70 in one minute. Dermographism red, persistent, in the Romberg sustainable. ECG - no change. Blood count: HB - 150 g/l, leucocytes of 5.5×109/l (e - 1, P - 1, p - 68, L - 25, M - 5). Bilirubin total to 18.5 µmol/l, direct - 1,4; alkaline phosphatase - 80,4 u/l; ALT - 31,4 u/l; AST - 21.6 u/l; GGT - 30 u/l, cholesterol - 5.8 mmol/l; LDH - 270 u/l; ck - 120 u/l; lactate - 1.8 mmol/l; pyruvate - 0.3 mmol/l; glucose - 5.1 mmol/l; amylase blood 110 u/l; uric acid - 320 µmol/l; catalase - 0,35 mkat/l; MDA - 3.3 µmol/l; the average molecule - 0.20 c.u; SAKR - moderate decrease in autonomic activity, minor parasympathicotonia. Improved emotional performance on psychological tests. The result of the treatment is improved.

2. Patient MAA, 68 years of age, was treated in Zheleznovodsk clinic FGI "Pyatigorsk, GNIIT FMBA of Russia" 19.05 on 08.06. 2011 (case history No. 838). Diagnosis: chronic gastroduodenitis in remission. Chronic acalculous cholecystitis in remission. Arterial hypertension II-senior risk I. Working with radioactive substances. Privrzenost 1 list. The duration of 20 years. Start zabolevaniya 1980. Were outpatients and inpatient without much effect Spa treatment for the first time. Complaints at admission: expressed General weakness, irritability, depressed mood, frequent headaches, pain in the epigastric region, heaviness in the right hypochondrium, bitter taste in the mouth. Palpation of the abdomen - sensitivity in the epigastrium and right hypochondrium, the liver on the edge of the costal arch, painless, spleen not palpated. Objective: HELL 160/90 mm Hg, pulse 76 in one minute. Dermographism red, spilled, the instability in the Romberg position. ECG: sinus bradycardia. Signs of hypertrophy of the left ventricle and left atrium. Blood count: HB - 138 g/l; leukocyte count of 5.2×109/l (e - 1, P - 2, p - 66, L - 25, M - 6). Bilirubin total - 17.5 µmol/l; direct - 1.4; alkaline phosphatase - 120 u/l; ALT - 17.5 u/l; AST - 29.7 u/l; GGT 33.6 u/l; cholesterol - 7.1 mmol/l; LDH - 298 u/l; ck - 153 u/l; lactate - 1.6 mmol/l; pyruvate - 0.08 mmol/l; glucose 5.5 mmol/l; amylase blood 112 u/l; uric acid - 364 μmol/l; catalase - 0,22 of MCAT/l; MDA - 3.6 µmol/l; the average molecule - 0,28 c.u; SAKR - reduced autonomic activity, expressed sympathicotonia. Ultrasound - structural changes in the liver, thickening of the gallbladder wall. The patient is assigned gently-training regimen physical activity, diet, scheme No. 5, internal reception Slavophiles sulphate-hydrocarbonate n is travo-calcium mineral water Slavyanovskaya source 250 ml 3 times a day for 45 minutes before a meal, mineral baths from the identical mineral water temperature 37°C, exposure of 15 minutes, in the course of 10 treatments. The patient took Adaptol 500 mg 3 times a day for 14 days, the sessions of psychological auditory training with aromatherapy. As a result of sanatorium-resort treatment has shown positive dynamics of clinical and paraclinical parameters. Decreased General weakness, disappeared irritability, headaches, decreased pain in the right hypochondrium and dyspeptic symptoms. Palpation of the abdomen painless. The liver is not enlarged. Objective: HELL 140/90 mm Hg, pulse 60 in one minute. Dermographism red spilled, the instability in the Romberg position. ECG - no change. Blood count: HB - 140 g/l; leukocytes of 5.0×109/l (e - 1, P - 2, p - 58, L - 32, M - 7). The total bilirubin is 16.1 µmol/l; direct - 1,5; alkaline phosphatase - 110 u/l; ALT - 17,5 u/l; AST - 26,2 u/l; GGT - 31.4 u/l; cholesterol - 5.8 mmol/l; LDH - 286 u/l; ck - 132 u/l; lactate - 1.6 mmol/l; pyruvate - 0.08 mmol/l; glucose - 5.3 mmol/l; amylase blood - 100 u/l; uric acid - 228 μmol/l; catalase - 0,38 of mkat/l; MDA - 3.0 µmol/l; the average molecule - 0.20 used; SAKR - normalization of vegetative regulation. Improved emotional performance on psychological tests. The result of the treatment is improved.

3. Patient DTI, 55 years of age, was treated in Zheleznovodsk clinic FGI "Pyatigorsk GNII the FMBA of Russia" 27.02 on 19.03.2011, (history No. 271). Diagnosis: chronic superficial gastritis, the remission phase. Chronic acalculous cholecystitis, phase incomplete remission. IBS with constipation. Works on impressedthe. Privrzenost 2-list - monoxide, fluoride products, butylene. The duration of 20 years. Onset - 2001. Were outpatients without much effect. Spa treatment for the first time. Complaints at admission: expressed General weakness, fatigue, irritability, frequent headaches, dizziness, insomnia, periodic pains in the heart area. Pain in the stomach after eating, a feeling of heaviness in the right hypochondrium, heartburn, burning sensation in the epigastric region, bloating, constipation. Inspection of the skin and visible mucous membranes of normal color. Palpation of the abdomen is determined by the tenderness in the epigastrium, in the right hypochondrium and in the area of the projection of the pancreas. The liver increased by 1.0-1.5 cm, sensitive to palpation. Spleen not palpated. Objective: the HELL of 145/90 mm Hg, pulse 72 in one minute. Dermographism spilled red, persistent instability in the Romberg position. ECG: incomplete blockade of the right leg PGIs, signs of repolarization of the left ventricle. Blood count: HB - 133 g/l; leukocyte count of 5.9×109/l (e - 1, P - 1, p - 71, L - 20, M - 7). B is Liubin General 26,3 µmol/l; direct - 2,9; alkaline phosphatase - 120 u/l; ALT - 27.9 u/l; AST - 25.2 u/l; GGT - 24.6 u/l; cholesterol - 6.8 µmol/l; LDH - 329 u/l; ck - 227 u/l; lactate - 2.4 mmol/l; pyruvate - 0.09 mmol/l; glucose of 6.1 mmol/l; amylase blood - 87,2 u/l; uric acid - 394 μmol/l; catalase - 0,26 km MCAT/l; MDA - 5.8 mmol/l; average molecule - 0,30 c.u; SAKR - moderate decrease in autonomic activity, sympathicotonia. Ultrasound enlarged right lobe of the liver, increased echogenicity, the gallbladder is enlarged (38×102 mm), concentrated bile, slight changes in the pancreatic parenchyma. The patient is assigned gently-training regimen physical activity, diet, scheme No. 5, internal reception Slavophiles sulphate-hydrocarbonate sodium-calcium mineral water Slavyanovskaya source 250 ml 3 times a day for 45 minutes before a meal, mineral baths from the identical mineral water temperature 37°C, exposure of 15 minutes, in the course of 10 treatments, psychological sessions of autogenic training with aromatherapy. The patient has been Adaptol 500 mg 3 times a day after meals for 14 days. As a result of sanatorium-resort treatment has shown positive dynamics of clinical and paraclinical parameters. When the extract decreased the heaviness in the right hypochondrium and bloating, weakness, improved mood and sleep was normalized. Preparatio abdominal pain were observed, the liver was increased by 1 cm, spleen not palpated.

Objective: HELL 140/90 mm Hg, pulse 68 in one minute. Dermographism red spilled, the instability in the Romberg position. ECG - no change. Blood count: HB - 134 g/l; leukocyte count of 6.0×109/l (e - 1, P - 2, p - 62, L - 29, M - 6). Bilirubin total - 17.5 µmol/l; direct - 1.2; alkaline phosphatase - 78,2 u/l; ALT - 25,2 u/l; AST to 21.1 u/l; GGT - 29.6 u/l; cholesterol - 5.3 mmol/l; LDH - 229 u/l; ck - 187 u/l; lactate - 2.0 mmol/l; pyruvate - 0.07 mmol/l; glucose of 5.5 mmol/l; amylase blood - 70,0 u/l; uric acid - 300 µmol/l; catalase - 0,30, mkat/l; MDA - 5.0 mmol/l; average molecule - 0.25 c.u; SAKR - normalization of autonomic activity. Improved emotional performance on psychological tests. The result of the treatment is improved.

The method was tested in conditions of Zheleznovodsk clinic Pyatigorsk state of GNIIT the FMBA of Russia on two groups of patients - main (30 people) and the comparison group (30 people)treated by the new method and the prototype, respectively. Patients on treatment received in the direction of the health parts of the FMBA of Russia from enterprises with harmful working conditions. The study included 60 patients - employees of the system of the FMBA of Russia, men-39 (65%), women - 21 (35%). The age of most patients 30 to 50 years (53,3%), 50 to above years to 46.7%. The number of engineering and technical worker who was in 23(38.3 per cent), working - 37 (61.7 per cent). The presence of privrzenost was noted in all patients, of which ionizing radiation in 32 (53.3 percent) patients, exposure to toxic chemicals in 21 (35%), psychological overload 7 (11,7%) patients.

We observed patients with pathology of the digestive system: ulcer of the duodenum and stomach, 17 (28.3% of patients), chronic gastritis in 27 (45%), chronic acalculous cholecystitis, 17 (28.3% of patients), chronic pancreatitis in 18 (30%). Was also observed comorbidities in the form of arterial hypertension - in 22 (36.7 per cent of patients). Clinical characteristics of patients are shown in table 1.

Marked manifestations of the three main syndromes - astheno-neurotic in 48 (80%) of patients with dyspepsia in 36 (60%) and pain - 35 (58.3 percent) of the patients.

Astheno-neurotic syndrome patients expressed General weakness, headaches, irritability, sleep disorders, some of them - depressive manifestations. Dyspeptic syndrome was due to the presence of diseases of the digestive system and manifest a feeling of heaviness in the right hypochondrium and epigastric region (45,0% of patients), heartburn (53,3%), bloating (45%), bitter taste in the mouth (28,3% of patients), violations of the chair in the form of constipation (31,7%) and breaks a chair (10% of patients). Tenderness to palpation in the region of epigastria noted in 34 (56,7%) patients, in the right hypochondrium in 16 (26.7 per cent) patients, in the left hypochondrium, 17 (28.3 per cent), in the course of bowel in 18 (30%) patients, a slight increase in the size of the liver was observed in 17 (28.3 per cent) patients. The functional state of the liver was characterized by violations of such syndromes as cholestatic (increased levels of bilirubin to 25.5±0,17 mmol/l and cholesterol to 6.92±0.46 mmol/l) and to a lesser extent cytolytic (increased ALT levels to 51.2±0,13 E/l and ACT to 45.3±0,18 u/l). A slight increase thymol turbidity of the samples was observed only in 18.3% of patients. There was an increase of activity of alkaline phosphatase is alkaline phosphatase to 127.5±1,13 u/l and violation peroxide homeostasis (increased concentrations of malondialdehyde - MDA to 6.4±0.07 µmol/l on the background of the decrease of catalase activity to 24,52±1,17, mkat/l). The level of middle molecules in the blood was increased to 0.32±0.21 in mkat/l, indicating that the violation of detoxification and strengthening of anaerobic metabolism.

In the study of psychological tests increased level of anxiety was detected in 45% of patients, depression in 36.7%. It should be noted that in the mental state of the patients lacked the characteristic features of endogenous depression (vitality color of passion, early waking, seasonality). This allowed us to relate depression to amatureallure States neurotic level. The questionnaire SAN malaise is Pradelles - at 35%, low activity - 40% of depressed mood in 33.3% of patients. Clinical questionnaire neurotic condition of the patients revealed the so-called "neurotic protection" in the form of headaches, constant fatigue, fatigue, weakness, sleep disorders.

In the analysis of the indices of nonspecific resistance (Poland) body noted that in a state of chronic stress were 66.7% of patients, and in an area of high activation - 25%. Data spirometery-cardiotocography showed high reactivity and low back and adaptation opportunities more than half of the workers from hazardous conditions.

After treatment in both groups noted the favorable dynamics of the main clinical manifestations of chronic fatigue syndrome and comorbidity. Comparative analysis showed that 1.5 times more pronounced changes were observed in the main group of patients with the use of additional Adaptol (table 2, 3).

Table 2
The dynamics of the main syndromes in the first main group of patients (n=30)
IndexThe presence before the treatmentN is existence after the treatment % improvement
Astheno-neurotic25-83,3%7-23,3%72%
Dyspeptic20-66,7%3-10%85%
Pain16-53,3%2-6,6%87,5%

Table 3
The dynamics of the main syndromes II in the comparison group(n=30)
IndexThe presence before the treatmentAvailability after treatment% improvement
Astheno-neurotic23-76,7%11-36,7%52,2%
Dyspeptic16-53,3%5-16,6%68,8%
Pain19-63,3%8-26,6%57,9%

In both groups of patients Norma who was inovalis levels of bilirubin, ALT activity and ACT, alkaline phosphatase, middle-sized molecules and blood thymol turbidity test. Less dynamic were indicators of cholesterol. It should be noted the expressed positive effect of the treatment on the performance FLOOR and antioxidant system in both groups decreased increased levels of malondialdehyde and increased catalase activity, more pronounced trend was observed in the main group of patients (table 4).

Table 4
The dynamics of the levels of malondialdehyde and catalase in serum
IndexThe main groupThe comparison group
Before the treatmentAfter the treatmentBefore the treatmentAfter the treatment
Malonic dialdehyde (µmol/l)6,4±0,093,6±0,16,3±0,15,2±0,11
p<0,05p>0,05
Catalase (mkat/l) 24.22 to±1,2431,12±1,324,81±1,1928,41±1,22
p<0,05p<0,05

After treatment according to the measure of nonspecific resistance (Poland) the percentage of patients in a state of chronic stress in group I decreased from 73.3% to 16.7% (p<0.05)and in group II - from 60% to 30% (p>0,05), i.e.% improvement in group I patients was 1.9 times higher than that of in group II (56,6% vs. 30%). When analyzing the performance SAQR total capacity of neuroendocrine regulation in group I increased from 1934,3 units to 2421,2% (p<0.05), in group II patients, the increase turned out to be false and made with 1899,8 units to 2001,3 unit (p>0,05). Confirmation of a significant improvement of adaptive reserves of the patients of the first main group, where he applied resort factors in combination with psycho - and pharmacotherapy were estimates of emotional indicators on psychological tests. The level of anxiety in the study group decreased from 0.15±0.12 points to 0.08±0,07 (p<0.05) in 9 of 15 (60% improvement), level of depression decreased with 0,58±0.41 points to 0.33±0,27 (p<0.05) in 9 of 12 patients (75% improvement). It should be noted that a significant decrease in anxiety in patients of the main group, where he was additionally appointed farmacopea the t Adaptol, and the level and frequency (60% improvement) is very important, when you consider that the anxiety is classified as a state of maximum biological stress, specific physiological response of the Central nervous system while hyperthyroidism and dysfunction of all vegetative structures. In the comparison group level of anxiety decreased from 0.13±0.17 to 0,11±0,18 (p>0,05) in 4 out of 12 (33.3% of improvement), and the level of depression - with 0.55±0.31 to 0,43±0,22 (p>0,05) in 5 people out of 10 (50% improvement). According to the SAN questionnaire indicators of health, activity and mood equally often improved in both groups of patients. Direct therapeutic efficacy (table 5) for the purpose I of the main medical complex with the use of resort factors, psychotherapy and drug Adaptol amounted to 93.3%, II medical complex - resort factors and psycho-correction without pharmacotherapy - 66,7% (p<0.05).

Table 5
The effectiveness of rehabilitation of persons with harmful working conditions
IndexSignificant improvementThe result of the treatment
improvementwithout change
The main group n=3010-33,3%18-60%2-6,7%
Comparison group n=305-16,7%15-50%10-33,3%
Total n=6015-25%33-55%12-20%

Thus, studies give reason to draw conclusions about the advantage of the combined use natural resort factors, psycho-correction and pharmacopaeia of Adaptol in achieving therapeutic efficacy of rehabilitation treatment of workers with harmful working conditions compared to traditional Spa therapy, which is explained by activating and article concludes that the action of the resort factors, psychotherapy and drug Adaptol on the processes of sanogenesis to enhance adaptive reserves of the body, improve autonomic regulation and emotional status of employees of enterprises with harmful working conditions.

Method of enhancing the adaptive capacity and correction psychofunctionalism status in patients with harmful working conditions, which includes gentle or gently-training regimen physical activity,healthy food in the diet №5, internal reception mineralized (3.7 g/DM3) Slavophiles sulphate-hydrocarbonate calcium-sodium mineral water Slavyanovskaya source (Zheleznovodsk type of mineral waters) of 3.3 g/kg body weight (200-250 ml) for one admission 45 minutes before meals, 3 times a day, the use of mineral baths with mineral water of identical composition at a water temperature of 36-37°C for 15 min, every other day, 10 sessions of treatment sessions and psychological auditory training with aromatherapy within 14 days, characterized in that it further has appointed internal reception of pharmacopaeia - Adaptol within 14 days 500 mg 3 times per day.



 

Same patents:

FIELD: food industry.

SUBSTANCE: invention relates to therapeutic nutrition for dietary control of depression and/or anxious disorder. The nutrition includes water containing 0.0002 - 0.0278 mol % of HOD isotopologue. The method for dietary control of depression and/or anxious disorder involves a stage of the said therapeutic nutrition administration to a person in need thereof.

EFFECT: one proposes a method for treatment of an anxious disorder with a person in need thereof, envisaging the following steps: (a) anxiolytic administration to the person and (b) the said therapeutic nutrition administration to the person.

5 cl, 7 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) and salts thereof wherein R1 represents -A11-A12-; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 3,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl containing methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine. Also, the invention also refers to a pharmaceutical composition possessing corticotrophin-releasing factor (CRF) receptor antagonist activity, containing a compound of formula (I), to a therapeutic/preventive agent, and a method of treating the diseases specified in the patent claim.

EFFECT: there are presented the compounds of formula (I) as corticotropin-releasing factor (CRF) receptor antagonists.

20 cl, 2 dwg, 2 tbl, 51 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (1), in which Ar is a group of formula (Ar-1) or (Ar-2), in which R1 is a halogen, R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, alkyl or alkenyl, X is a nitrogen atom or CH, R5 and R6 are each hydrogen and h equals 1; 1 equals 1 or 2; m equals 1 or 2; n equals 0, 1 or 2; o equals an integer from 0 to 3, under the condition that n and o are equal to 0 at the same time. Values of group A are as given in claim 1 of the invention. Described also is a pharmaceutical composition having agonistic activity with respect to 7 serotonin (5-HT4-receptors), which contains a compound of formula (1) and an agent which stimulates enterokinesis or improves functioning of the alimentary canal, which contains a compound of formula (1) as an active ingredient.

EFFECT: novel compounds are obtained and described, which have strong affinity towards 4 serotonin receptors, which are useful as an agent which stimulates enterokinesis or an agent which improves functioning of the alimentary canal.

28 cl, 233 ex, 29 tbl

FIELD: food industry.

SUBSTANCE: invention relates to therapeutic nutrition for dietary control of depression and/or anxious disorder. The nutrition includes water containing 0.030 - 0.197 mol % of isotopologue H218O. The method for dietary control of depression and/or anxious disorder involves a step of the said therapeutic nutrition administration to a person in need thereof.

EFFECT: one proposes a method for treatment of depression with a person in need thereof, envisaging the following steps: (a) antidepressant administration to the person and (b) the said therapeutic nutrition administration to the person.

5 cl, 7 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds - substituted 1,3-diethyl-8-vinyl-7-methyl-3,7-dihydropurine-2,6-diones of general formula 1, which exhibit antagonist activity on adenosine A2A receptors. The compounds can be used as an active source of a medicinal agent or adjuvant for pharmaceutical compositions and medicinal agents. The invention also relates to a method of inhibiting and a method of treating diseases of the central nervous system, oncological, viral and bacterial diseases which are mediated by adenosine A2a receptor activity. In general formula 1 , where: Ar is 2,5-dimethoxyphenyl, 4-isobutoxy-3-methoxyphenyl, 3-phenoxyphenyl substituted with pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, C1-C5alkoxy group, amino group, optionally substituted with a mono- or di-C1-C5alkyl; 3-methylthiophen-2-yl, pyrazol-4-yl, substituted with C1-C5alkyl; 2,3-dihydro-benzo[1,4]dioxin-6-yl, optionally substituted with C1-C5alkoxycarbonyl, carbamoyl, which is optionally substituted with mono- or di-C1-C5alkyl, or carbonyl-piperazine, optionally substituted with C1-C5alkyl.

EFFECT: improved properties.

13 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of general formula

, wherein X represents a halogen atom or C1-6-alkyl; and has the value of 0, 1, 2 or 3; R1 represents H; R2 represents or ; R3 represents C1-6-alkyl, C3-10-cycloalkyl, phenyl, 6-member heterocycloalkyl representing tetrahydropyranyl, or 5-10-member heteroaryl specified in pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzo[1,3]dioxolyl and 2,3-dihydrobenzo[1,4]dioxynyl; which be substituted and contains one to five substitutes specified in the patent claim. The invention also refers to pharmaceutical compositions possessing high affinity to dopamine D3 receptor and serotonin 5-HT2A receptor containing said compounds, and the use thereof in preparing drugs.

EFFECT: preparing the compounds of formula (I) possessing high affinity to dopamine D3 receptor and serotonine 5-HT2A receptor.

15 cl, 4 dwg, 5 tbl, 78 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely physiology, pathophysiology and pharmacology, and may be used for an anxiolytic (antianxiety) effect. Substance of the invention consists in the use of peptide Gly-His-Lys of formula (NH2)Gly-His-Lys(COOH) for the anxiolytic effect. The experimental use of peptide Gly-His-Lys in single doses of 0.5 and 5 mcg/kg of body weight 12 minutes before the beginning of the examination causes the manifested anxiolytic effect.

EFFECT: invention provides the use of peptide Gly-His-Lys by the new application, namely for anxiolytic action.

1 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new substituted phenoxyacetic acids of general formula 1 possessing the properties of a selective antagonist inhibiting A2a adenosine receptor activity. The compounds may be used in preventing and treating central nervous system diseases, such as cognitive disorders, Parkinson's disease, or depression, tumour diseases, inflammatory processes. The invention also refers to an agent for intensification of immune response or action of drug preparations in the combination treatment of the diseases. In general formula

, R1, R2 and R3, optionally simultaneously represent hydrogen. C1-C5alkyl, C3-C5alkenyl or C3-C5-alkynyl; R4 represents hydrogen, a halogen atom, hydroxyl, C1-C3alkyl, C1-C3alkyloxy; R5 represents hydrogen, C1-C3alkyl, the group -C(O)R6;R6 represents hydroxyl, C1-C5alkyloxy, C3-C5alkenyloxy, C3-C5alkynyloxy optionally substituted by an amino group wherein the substitutes optionally identical are specified in hydrogen, C1-C3alkyl optionally substituted by a mono- or dialkylaminogroup, an alkyloxygroup, 5-6-member saturated heterocyclyl containing 1-2 heteroatoms specified in nitrogen and oxygen: pyridyl, phenyl optionally substituted by 1-3 methoxygroups; or optionally substituted 6-member, optionally annulated with 5-member unsaturated heterocyclyl, saturated heterocyclyl containing 2 nitrogen atoms wherein the substitutes are specified in C1-C3alkyl optionally substituted by 5- member heteroaryl containing 1-3 heteroatoms specified in nitrogen and oxygen; or 6- member optionally saturated heterocyclyl containing 1-2 nitrogen atom optionally substituted by C1-C3alkyl, oxo, optionally substituted by phenyl; a dashed line with an accompanying continuous line represents a single, double or triple bond.

EFFECT: preparing new substituted phenoxyacetic acids of general formula 1 possessing the properties of the selective agonist inhibiting A2a adenosine receptor activity.

15 cl, 3 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely psychiatry and may be used for treating depression. For this purpose, a therapeutically effective amount of a combination of telenzepine and one or more antidepressants specified in a group consisting of fluoxetine, sertraline and venlafaxine are introduced in an individual in need thereof. There are also presented a pharmaceutical composition and a kit for treating depression.

EFFECT: group of inventions provides treating depression in an individual, as well as more intensive antidepressant action, than that ensured by introducing any of said drugs separately.

15 cl, 6 dwg, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition for treating and/or preventing depressions. The pharmaceutical composition contains an active substance presented by a selective serotonin reuptake inhibitor (SSRI) specified in a group of fluoxetine, paroxetine, citalopram, escitalopram, sertraline, fluvoxamine differing by the fact that as an active substance, it additionally contains N-acetyl-5-methoxytryptamine (melatonin) in the following proportions, mg: selective serotonin reuptake inhibitor (SSRI) - 10-30 mg, melatonin - 3-8 mg. The pharmaceutical composition may be presented by a solid dosage form - a tablet, a film-coated tablet, a capsule, by a soft dosage form - a rectal suppository.

EFFECT: pharmaceutical composition provides treating depressions and has a number of additional therapeutic properties: easing falling asleep and relieving sleeping disorders, recovering circadian rhythm and seasonal rhythm with reducing a risk of side effects of SSRI.

3 cl, 14 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to solid fast-disintegrating dosage form of medication with antiparkinsonian action, which contains as active pharmaceutical ingredient memantine and/or memantine hydrochloride and cellulose II with the following ingredient ratio, wt %: memantine and/or memantine hydrochloride - 5-10, cellulose II - 90-95. Dosage form can represent pellet, created by method of direct pelletting.

EFFECT: obtaining fast-disintegrating in oral cavity dosage form, its distribution throughout oral cavity and delay of its transport to stomach, in order to provide medication delivery, not entering gastrointestinal tract and eliminating metabolism of medication in liver.

2 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to method of obtaining aripiprazole suspension. Method includes the following stages: (a) combining aripiprazole mass and carrier with formation of primary suspension; (b) first refining of primary suspension with obtaining secondary suspension using apparatus for refining with large shearing force, dispersant, in which shearing force is applied for material processing, or high-pressure homogeniser; and (c) second refining of secondary suspension with obtaining final sterile suspension by high-pressure homogeniser. Claimed composition also relates to methods of obtaining lyophilysed composition from aripiprazole suspension.

EFFECT: claimed invention provides possibility of obtaining aripiprazole suspension with the average size of particles from 1 to 10 mcm, without necessity to use special crystallisation technologies for obtaining initial aripiprazole mass and without application of vacuum mixing at the stage of combining aripiprazole mass and carrier.

33 cl, 13 tbl, 15 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel quinoline compounds of formula (I) and physiologically acceptable acid addition salts and N oxides thereof, wherein R denotes a polycyclic group of formula (R) wherein * indicates the quinolinyl radical binding site; A denotes (CH2)a, where a equals 0, 1, 2 or 3; B denotes (CH2)b, where b equals 0, 1, 2 or 3; X' denotes (CH2)x where x equals 0, 1, 2 or 3; Y denotes (CH2)y where y equals 0, 1, 2 or 3; provided that a+b=1, 2, 3 or 4, x+y=1, 2, 3 or 4, and a+b+x+y=3, 4, 5, 6 or 7; Q denotes N; R1 denotes hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl-C1-C4-alkyl, phenyl-C1-C4-alkyl, C1-C4-alkylcarbonyl, C1-C4-alkoxycarbonyl, phenoxycarbonyl or benzyloxycarbonyl, where phenyl rings in last two said groups are unsubstituted or carry 1, 2 or 3 substitutes selected from halogen, C1-C4-alkyl or C1-C4-halogenalkyl; R2 denotes hydrogen; R3 denotes hydrogen; p=0, 1 or 2; R4, if present, denotes C1-C4-alkyl and is bonded with X and/or Y, if p=2, two radicals R4, which are bonded with adjacent carbon atoms of X or Y, together can also denote a straight C2-C5-alkylene; q=0; n=0; m=0; X denotes S(O)2; which is located in position 3 of quinoline; Ar denotes a radical Ar1, wherein Ar1 is a phenyl, wherein the phenyl can be unsubstituted or can carry 1 substitute Rx wherein Rx denotes halogen, CN, C1-C6-alkyl, C1-C6-halogenalkyl, C1-C6-alkoxy, C1-C6-halogenalkoxy, C1-C6-alkylthio, C1-C6-halogenalkylthio, NRx1 Rx2, wherein Rx1 and Rx2 independently denote hydrogen, C1-C6-alkyl, or Rx1 and Rx2 together with a nitrogen atom form an N-bonded 5-, 6- or 7-member saturated heteromonocyclic ring or an N-boned 7-, 8-, 9- or 10-member saturated heterobicyclic ring, which are unsubstituted or carry 1, 2, 3 or 4 radicals selected from C1-C4-alkyl. The invention also relates to a pharmaceutical composition based on the compound of formula (I), a method of treatment using the compound of formula (I) and use of the compound of formula (I).

EFFECT: novel quinoline derivatives are obtained, which respond to modulation of the serotonin 5-HT6 receptor.

23 cl, 2 tbl, 44 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new gamma-secretase inhibitors of formula I: , wherein L1,R1, R2,X,n and Ar have the values specified in the description, their pharmaceutically acceptable salts and solvates, as well as to pharmaceutical compositions based on these compounds for treating Alzheimer's disease and the use of drugs for gamma-secretase and beta-amyloid protein inhibition, and for treating neurodegenerative diseases such as Alzheimer's disease.

EFFECT: preparing the compound for treating the neurodegenerative diseases.

38 cl

FIELD: chemistry.

SUBSTANCE: invention refers to compounds of formula I: wherein a dash line represents an optional double bond; R1 means phenyl, naphthyl, pyridyl optionally substituted by one or two substitutes optionally substituted from halogen, C1-C6 alkyl, mono-halo C1-C6 alkyl, di-halo C1-C6 alkyl, CF3; R2 means H, methyl, halogen; R3 and R4 optionally mean, CF3, halo, C1-C3 alkyl wherein C1-C3 alkyl groups are optionally substituted by one or more halogen atoms; X=O; q=0; R5 means C1-C6 alkyl or its pharmaceutically acceptable salt.

EFFECT: compounds possess potassium channel modulating activity that enables using them in pharmaceutical compositions.

28 cl, 1 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatric neurology, and can be used for rehabilitation of neurological disorders in children in case of neuroinfections. For this purpose, at the background of adequate complex and pathogenetic therapy, parenteral introduction of actovegin in acute period of disease additionally from the first days of disease cytoflavin is introduced intravenously by drop infusion in dose 0.6 ml/kg or 10 ml per day for 3-5 days, elcar perorally in dose 70-100 mg/kg of weight per day for 3-4 weeks. In the period of early reconvalescence pantogam is additionally introduced perorally in dose 50-70 mg/kg of weight per day for 4 weeks. In case if multifocal affection of brain substance is present, gliatilin is introduced intravenously by drop infusion in dose 1 ml per 5 kg of body weight per day in combination with intramuscular introduction of ipidacrine in dose 5-15 mg per day for 7-10 days, after that gliatilin perorally in dose 50 mg/kg of weight per day together with ipidacrine inside in dose 1 mg/kg per day for 4 weeks.

EFFECT: method makes it possible to improve disease outcome due to reduction of frequency of residual neurological deficiency formation with reduction of term of hospital treatment.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to field of pharmacology and clinical medicine and describes pharmaceutical compositions of 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diole in free form and/or in form of pharmaceutically acceptable salt, where as auxiliary substances they contain lactose, starch and/or starch derivatives, selected from acetylated starch, sodium salt of starch carboxymethyl ether, pregelatinised starch, sodium starch glycolate, gelatin, binding agent, and lubricant with specified ratio.

EFFECT: invention makes it possible to extend possibility for cheaper in industrial manufacturing preparation for treatment of disseminated sclerosis.

7 cl, 16 ex

FIELD: food industry.

SUBSTANCE: invention relates to therapeutic nutrition for dietary control of depression and/or anxious disorder. The nutrition includes water containing 0.0002 - 0.0278 mol % of HOD isotopologue. The method for dietary control of depression and/or anxious disorder involves a stage of the said therapeutic nutrition administration to a person in need thereof.

EFFECT: one proposes a method for treatment of an anxious disorder with a person in need thereof, envisaging the following steps: (a) anxiolytic administration to the person and (b) the said therapeutic nutrition administration to the person.

5 cl, 7 tbl, 7 ex

FIELD: food industry.

SUBSTANCE: invention relates to therapeutic nutrition for dietary control of depression and/or anxious disorder. The nutrition includes water containing 0.0002 - 0.0278 mol % of HOD isotopologue. The method for dietary control of depression and/or anxious disorder involves a stage of the said therapeutic nutrition administration to a person in need thereof.

EFFECT: one proposes a method for treatment of an anxious disorder with a person in need thereof, envisaging the following steps: (a) anxiolytic administration to the person and (b) the said therapeutic nutrition administration to the person.

5 cl, 7 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) and salts thereof wherein R1 represents -A11-A12-; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 3,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl containing methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine. Also, the invention also refers to a pharmaceutical composition possessing corticotrophin-releasing factor (CRF) receptor antagonist activity, containing a compound of formula (I), to a therapeutic/preventive agent, and a method of treating the diseases specified in the patent claim.

EFFECT: there are presented the compounds of formula (I) as corticotropin-releasing factor (CRF) receptor antagonists.

20 cl, 2 dwg, 2 tbl, 51 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, and may be used for treating suppurative septic complications of prostate adenoma. For this purpose, with underlying administering antibiotics, ozonised saline solution in the concentration of 3 to 6 mg/l in the amount of 200 to 400 ml is additionally intravenously administered; the therapeutic course is 3-5 injections depending on the patient's state. Besides, ozonised saline solution in the concentration of 5 to 8 mg/l is injected into the bladder in the preoperative preparation period, and from the second postoperative day, saline solution is introduced drop-by-drop in the amount of 400.0 ml daily five times with a two-way flushing system.

EFFECT: method enables reducing the risk of urosepsis, eliminating intoxication and accelerating postoperative wound healing of a BPH bed by anti-inflammatory, detoxification, analgesic action, improved blood rheology and microcirculation, increased local immunity with activated regenerative and reparative processes.

2 tbl, 1 ex

Up!